药明生物2024年年报点评:临床前收入快速恢复,整体项目数稳步提升

光大证券
27 Mar

要点事件:公司发布2024年业绩公告,实现收入186.75亿元(YOY+9.6%);实现归母净利润33.56亿元(YOY-1.3%);实现经调整纯利54.0亿元(YOY+9.0%);其中非新冠业务收入同比增长13.1%至约186.8亿元;业绩略低于我们此前预期。点评:临床前业务恢复强劲,整体项目数持续增加。24年公司实现临床前服务收入70.62亿元(YOY+30.7%),远高于公司整体收入增速,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10